Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience.
Fair
W R
WR
Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Scher
H
H
Herr
H
H
Morse
M
M
Sogani
P
P
Bosi
G
G
Dershaw
D
D
Reuter
V
V
Curley
T
T
Bosh
G
G
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D010865:Pilot Projects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate